Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
Exelixis, Inc. (EXEL) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
01:41pm, Monday, 10'th Nov 2025
Exelixis, Inc. ( EXEL ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10, 2025 10:30 AM EST Company Participants Michael Morrissey - CEO, President & Director Conference C
Exelixis: The STELLAR Win Is A Mixed Bag, But Things Look Positive Still
09:39pm, Thursday, 06'th Nov 2025
Exelixis is positioned for growth with positive phase 3 data for zanzalintinib in metastatic colorectal cancer, following cabozantinib's success. STELLAR-303 results show modest survival benefit but i
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
04:05pm, Thursday, 06'th Nov 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November: Guggenheim
EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales
11:56am, Wednesday, 05'th Nov 2025
Exelixis posts strong Q3 results with earnings and revenue beats, boosted by Cabometyx sales, and narrows 2025 guidance.
Exelixis, Inc. (EXEL) Q3 2025 Earnings Call Transcript
09:06pm, Tuesday, 04'th Nov 2025
Exelixis, Inc. ( EXEL ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Susan Hubbard - Executive Vice President of Public Affairs & Investor Relations Michael Morrissey - CEO,
Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
07:31pm, Tuesday, 04'th Nov 2025
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street est
Exelixis (EXEL) Beats Q3 Earnings and Revenue Estimates
06:56pm, Tuesday, 04'th Nov 2025
Exelixis (EXEL) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.47 per share a year ago.
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 04'th Nov 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2025, provided an update on progress toward achieving key corporate objectives
Oppenheimer Asset Management Inc. Takes Position in Exelixis, Inc. $EXEL
03:59am, Monday, 03'rd Nov 2025
Oppenheimer Asset Management Inc. acquired a new stake in Exelixis, Inc. (NASDAQ: EXEL) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The
AlphaQuest LLC Acquires 8,339 Shares of Exelixis, Inc. $EXEL
05:44am, Thursday, 30'th Oct 2025
AlphaQuest LLC grew its holdings in Exelixis, Inc. (NASDAQ: EXEL) by 867.7% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor
Ethic Inc. Reduces Position in Exelixis, Inc. $EXEL
04:04am, Thursday, 30'th Oct 2025
Ethic Inc. trimmed its position in Exelixis, Inc. (NASDAQ: EXEL) by 12.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional
Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth
11:01am, Tuesday, 28'th Oct 2025
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
10:00am, Tuesday, 28'th Oct 2025
NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to c
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again
01:11pm, Monday, 27'th Oct 2025
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why Exelixis (EXEL) is a Strong Value Stock
10:41am, Monday, 27'th Oct 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
